Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares (CANF)
R&D Expense Growth
17.18%
Fiscal year · Period ending:
CANF R&D Expense Growth
Latest reported17.18%period ending
Latest reported17.18%period ending
CANF FY R&D Growth (YoY) (0.00% → 17.18%)
Latest values, visible window
High-resolution chart · PNG
CANF r&d expense growth history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expense Growth |
|---|---|
| 17.1807% | |
| -3.7774% | |
| -22.9293% | |
| -21.1878% | |
| -17.5801% | |
| 8.883% | |
| 80.6749% | |
| 15.24% | |
| -13.2687% | |
| 57.6323% | |
| -7.318% | |
| -5.8589% | |
| 25.456% | |
| 3.3757% | |
| 20.983% | |
| 0% |